Items Tagged ‘CTL119’

June 5, 2017

Personalized Cell Therapy Combined with Imbruvica Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients


Combining the kinase inhibitor Imbruvica (ibrutinib) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penn’s Abramson Cancer Center (ACC). The team will present the results from its pilot study […]

View full entry

Tags: Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, CTL119, ibrutinib, kinase inhibitor, Leukemia, News, Personalized Cell Therapy, personalized cellular therapy